EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors

Matthew K Wong, Giselle M Boukhaled, Eric Armstrong, Rachel Liu, Alya A Heirali, Noelle R Yee, Jinny Tsang, Pavlina Spiliopoulou, Pierre H H Schneeberger, Ben X Wang, Kyla Cochrane, Keith Sherriff und 4 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Matthew K Wong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Immunoglobulin G, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tomczyk Microbiome Initiative Fund, Conquer Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gut microbiome modulation has shown promise in its potential to treat cancer in combination with immunotherapy. Mechanistically, the pathways and routes by which gut microbiota may influence systemic and antitumor immunity remain uncertain. Here, we used blood and stool samples from Microbial Ecosystem Therapeutic 4 (MET4)-IO, an early-phase trial testing the safety and engraftment of the MET4 bacterial consortium in immune checkpoint inhibitor recipients, to assess how MET4 may affect systemic immunity.

Methods

Circulating antibody responses induced by MET4 were assessed using an antimicrobial antibody flow cytometry assay on pretreatment and post-treatment plasma. Antibody responses were associated with taxonomic changes in stool identified by metagenomic sequencing. Mass cytometry was performed on peripheral blood mononuclear cells to identify shifts in circulating immune subsets associated with antibody responses.

Results

Increases in circulating anti-MET4 immunoglobulin G (IgG) responses were measured by flow cytometry post-consortium treatment in MET4 recipients, but not untreated control participants, with five individuals displaying notably higher antibody responses. Stronger IgG responses were associated with greater increases in multiple taxa, including MET4 microbe Collinsella aerofaciens , which was previously linked with immune checkpoint response. However, these taxa were not enriched in the IgG-bound fraction post-MET4 treatment. Greater increases in circulating B cells and FoxP3 + CD4 + T cells post-MET4 treatment were observed in the blood of high IgG responders, while CD14 + and CD16 + monocyte populations were decreased in these individuals.

Conclusion

These results demonstrate the induction of treatment-specific circulating humoral immunity by a bacterial consortium and suggest potential mechanisms by which gut microbes may contribute to antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeImmune Checkpoint InhibitorsImmunoglobulin GNeoplasmsHumansFemaleMaleMiddle Aged

Stichwörter der Autor:innen

AntibodyCombination therapyImmune Checkpoint Inhibitor

Substanzen

Immune Checkpoint InhibitorsImmunoglobulin G

Autor:innen und Institutionen

  • Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • School of Cancer Sciences, University of Glasgow, Glasgow, UK.

Förderung

  • Tomczyk Microbiome Initiative Fund
  • Conquer Cancer Foundation

Zitieren

APA

Wong, M. K., Boukhaled, G. M., Armstrong, E., Liu, R., Heirali, A. A., Yee, N. R., Tsang, J., Spiliopoulou, P., Schneeberger, P. H. H., Wang, B. X., Cochrane, K., Sherriff, K., Allen-Vercoe, E., Siu, L. L., Spreafico, A., & Coburn, B. (2025). Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010681

Vancouver

Wong MK, Boukhaled GM, Armstrong E, Liu R, Heirali AA, Yee NR, et al. Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010681

BibTeX
@article{Wong2025,
  author = {Wong, Matthew K and Boukhaled, Giselle M and Armstrong, Eric and Liu, Rachel and Heirali, Alya A and Yee, Noelle R and Tsang, Jinny and Spiliopoulou, Pavlina and Schneeberger, Pierre H H and Wang, Ben X and Cochrane, Kyla and Sherriff, Keith and Allen-Vercoe, Emma and Siu, Lillian L and Spreafico, Anna and Coburn, Bryan},
  title = {Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010681}
}
Kostenlos starten →